Three life years gained after reperfusion therapy in acute myocardial infarction: 25−30 years after a randomized controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Three life years gained after reperfusion therapy in acute myocardial infarction: 25−30 years after a randomized controlled trial

Published:2011-10-19 Issue:6 Volume:19 Page:1316-1323
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:Eur J Prev Cardiolog

Author:

Domburg Ron T van¹,Hendriks Jeroen M²,Kamp Otto³,Smits Peter⁴,Melle Marije van⁴,Schenkeveld Lisanne¹,Bax Jeroen J⁵,Simoons Maarten L¹

Affiliation:

1. Erasmus Medical Center, Rotterdam, The Netherlands.

2. Maastricht University Medical Centre, Maastricht, The Netherlands.

3. VU University Medical Center, Amsterdam, The Netherlands.

4. Maasstad Hospital, Rotterdam, The Netherlands.

5. Leids University Medical Center, Leiden, The Netherlands.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Epidemiology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1741826711428064

Reference16 articles.

1. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

2. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

3. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

4. Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cardioprotective and antiarrhythmic effects of Nardostachys chinensis in animal and cell experiments;BMC Complementary and Alternative Medicine;2017-08-10

2. Timely treatment for acute myocardial infarction and health outcomes: An integrative review of the literature;Australian Critical Care;2014-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3